Article Information

Corresponding author: Dr Amit Sharma

Article Type : Short review

Volume : 2

Issue : 5

Received Date : 15 Jun ,2021


Accepted Date : 18 Jun ,2021

Published Date : 22 Jun ,2021


DOI : https://doi.org/10.38207/jmcrcs20210071

Citation: Sharma A, Sethi P, Arora P, Gupta A, Dewan RK. The Potential Role of the Multi-faceted Properties of Cholesterol Lowering Agents in the Management of the Dreaded Pandemic of Covid-19. J Med Case Rep Case Series 2(5): https://doi.org/10.38207/jmcrcs2021007

Copyright: © © 2021 Sharma A. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
  The Potential Role of the Multi-faceted Properties of Cholesterol Lowering Agents in the Management of the Dreaded Pandemic of Covid-19

Dr Amit Sharma1, *, Dr Prabhpreet Sethi1, Dr Puneet Arora1, Dr Amitesh Gupta2, Dr Ravindra Kumar Dewan3

1Chest Specialist, NITRD
2Medical Officer & ex-Senior Resident (Chest), NITRD
3Thoracic Surgeon and Director, NITRD

*Corresponding Author: Dr Amit Sharma, Chest Specialist, NITRD

#NITRD also functioned as Covid-19 Centre under the aegis of Ministry of Health and Family Welfare, Government of India, f. 01- 05-2021 and allotted around 100 beds for exclusive management of Covid-19 patients.

Humanity has rarely faced such a resilient and devastating adversary such as the current pandemic caused by the SARS-CoV2 Virus or simply Covid-19. It has wiped millions of people all around the Globe with relentless savagery. However, as always, we human beings are now learning more and more about this lethal enemy. A very great effort is being performed to find protection and cure and new drugs and vaccines are being discovered. Crucially we have been partly successful in repurposing the drugs for Covid-19 which were already being used for different purposes.

In this short review, we examine the anti-viral and anti-inflammatory properties of a drug that is used quite routinely in the management of Dyslipidaemias – Statins! It seems peculiar that the Covid-19 virus would be in any way susceptible to the effects of such a drug as the connection seems lacking. However, during the fatal Ebola Virus (EBOV) outbreak in West Africa, statins showed evidence of effectiveness in decreasing the infectivity by reduced processing of certain glycoproteins and they are subsequent entries in EBOV [1]. With the passage of time, there is accumulating evidence about the versatile properties of the Statins. The statins apart from their cholesterol-lowering effect also exhibit a multitude of Pleiotropic effects. Apart from being strong antioxidants, statins also exhibit several pleiotropic effects such as endothelial dysfunction improvement, increased nitric oxide bioavailability, anti- inflammatory action, and atherosclerotic plaque stability [2].

Much of the damage that occurs in Covid-19 Pneumonia is not by the virus per se but because of the strong inflammatory response of the body to it leading to a deluge of pro-inflammatory cytokines such as IL-1β, TNF-α, and IL-6, a process which is often described as the Cytokine storm [3]. With further progression, the organs start getting damaged, and ultimately death ensues. Hence it can be said that our own saviors turn upon us to wreak havoc and death, instigated by our lethal enemy, the Covid-19 virus.

There is some evidence which suggests that Statins when administered to Hospitalized patients with Covid-19 infection may lead to a favourable outcome. But there is still a lack of robust data to endorse the routine use of Statins in Covid-19 patients. Apart from EBOV, there are other viral infections in which statins have shown beneficial effects such as Influenza. The ARDS pattern seen in Covid- 19 infection is different from the usual ARDS. Though there is strong hypoxemia, there is somewhat preserved compliance of the lungs, something which is not typical of usual ARDS [4]. Hence, the respiratory distress may be disproportionately less as compared to the severity of hypoxemia. Moreover, a thrombo-embolic phenomenon because of hypercoagulability and dysfunctional endothelial response may be the chief cause of Covid related respiratory illness [5].

The protective role of statins in Covid-19 illness may also depend on the solubility of the drugs, whether hydrophilic (water-soluble) or lipophilic (fat-soluble). The target receptors through which the virus gains entry is present not only in the lungs but also in several other parts of the body such as adipose tissue and the central nervous system. Hence, in the case of lipophilic statins such as atorvastatin, the benefit may be more owing to their infiltration in the sites where hydrophilic Statins such as rosuvastatin may not be able to gain entry. This includes the blood-brain barrier and adipose tissue, the latter having a high number of ACE2 receptors [6].

Viral replication also depends a lot on lipid metabolism and the lipid- lowering properties of the Statins probably also play an important antiviral role in reducing the proliferation of the Virus. There is some concern about the adverse effects of Statins in hospitalized patients such as elevation of liver enzymes, dysglycemia, and myopathy. However, there is evidence to support the fact that this is not probably so and the potential benefit of statins in combating the illness may outweigh the risk of side effects [7].

Conclusion
To conclude, in the fight against this dreadful pandemic, repurposed drugs are showing promising results, and in this brief review, an attempt  has  been  made  to  highlight  the  potential  role  of   Statins especially the lipophilic ones such as atorvastatin in the Global anti-Covid 19 crusade. The advantages of low cost and a decreased risk of adverse effects further lends support to the utilization of this multifaceted class of agents for management of a dreadful disease. However, we need large, randomized trials to fully validate and endorse the role of the Statins in the Battle against Covid-19.

References

  1. Shrivastava-Ranjan P, Flint M, Bergeron É, McElroy AK, Chatterjee P, et al. (2018) Statins Suppress Ebola Virus Infectivity by Interfering with Glycoprotein Processing.m.bio.9(3).
  2. Davignon J (2004) Beneficial cardiovascular pleiotropic effects of statins. Circulation. 109(23 Suppl 1): III39-43.
  3. Jose RJ, Manuel A (2020) COVID-19 cytokine storm: the interplay between inflammation and coagulation. Lancet Respir Med. 8(6): e46-e47.
  4. Gattinoni L, Chiumello D, Caironi P, Busana M, Romitti F, et al. (2020) COVID-19 pneumonia: different respiratory treatments for different phenotypes? Intensive Care Med. 46(6): 1099-1102.
  5. Faqihi F, Alharthy A, Balhamar A, Nasim N, Alanezi K, et al. (2021) A Retrospective Analysis of Thromboembolic Phenomena in Mechanically Ventilated Patients with COVID-
  6. 19. Critical Care Research and Practice. 2021: 8737580.
  7. Rossi R, Talarico M, Coppi F, Boriani G (2020) Protective role of statins in COVID 19 patients: importance of pharmacokinetic characteristics rather than intensity of action. Intern Emerg Med. 15(8): 1573- 1576.
  8. Zhang XJ, Qin JJ, Cheng X, Shen L, Zhao YC, et al. (2020) In- Hospital Use of Statins Is Associated with a Reduced Risk of Mortality among Individuals with COVID-19. Cell Metab.  32(2): 176-187.e4.